ST. LOUIS, June 16, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will participate in Cardiostim 2014, the biennial scientific congress of the European Heart Rhythm Association (EHRA), to be held June 18-21, 2014 in Nice, France. The event represents the largest conference attended by the Company in Europe, expected to draw more than 5,600 electrophysiology (EP) and cardiology professionals from Europe and around the world.
"Building on a successful Heart Rhythm Society session in the U.S., we are excited to highlight our product advancements and the procedure efficiency, proven outcomes and unmatched safety profile of our technology to the EHRA congress," said William C. Mills, Stereotaxis Chief Executive Officer.
More than 500 EP physicians worldwide currently rely on Stereotaxis technology, with the largest volume of Stereotaxis procedures performed in the European Union, particularly in the treatment of atrial fibrillation. At Cardiostim (Booth C16), the Company will introduce participants to its enhanced user interface, which features Ablation History, a graphical display enabling physicians to retrace their ablation-related activity and potentially identify gaps in lesion lines on a real-time basis. The new feature is designed to arm physicians with visual intelligence on the applied treatment in order to improve procedure efficiency and outcomes. In addition, the Company will share new internal data substantiating comparable procedure times with manual methods for proficient Stereotaxis users.
During a lunch symposium on June 19, Stereotaxis physician users will present on "Efficiency Effectively Applied," speaking to their personal success with implementing the Company's magnetic navigation platform in their EP practices. Moderated by Professor Gerhard Hindricks of Herzzentrum Leipzig in Germany and Professor Hiroshi Nakagawa of the University of Oklahoma Health Sciences Center, the event's speakers include Dr. Bruno Schwagten (ZNA Middelheim, Middelheim, Belgium), Dr. Erik Wissner (Asklepios Hospital St. Georg, Hamburg, Germany) and Professor Pekka Raatikainen (Tampere University Hospital, Tampere, Finland).
In addition, two scientific sessions will feature an abstract and poster related to Stereotaxis technologies:
"Catheter Positioning During Pulmonary Vein Isolation Easier with Magnetic than Manual Techniques;" Dr. Gabriel Latcu, Princess Grace Medical Centre, Monaco
"Retrograde AF Approach with Stereotaxis;" Dr. Christine Lemes, Asklepios Hospital St. Georg, Hamburg, Germany
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch™ Solution includes the Niobe® ES Remote Magnetic Navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems and the Vdrive™ Robotic Navigation system and consumables.
The core components of Stereotaxis systems have received regulatory clearance in the U.S., European Union, Canada, China, Japan and elsewhere. The V-Sono™ ICE catheter manipulator has received U.S. clearance, and the V-Loop™ variable loop catheter manipulator and V-CAS™ catheter advancement system have been submitted for review by the U.S. Food and Drug Administration. For more information, please visit www.stereotaxis.com
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, the outcome of various shareholder litigation filed against Stereotaxis, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
CONTACT: Company Contact:
Chief Financial Officer
Todd Kehrli / Jim Byers
MKR Group, Inc.